clinical trial · NCT00833586
Terbinafine HCl 250 mg Tablet Under Fasting Conditions
Teva Pharmaceuticals USA·phase1·completed·n = 28
HealthyTerbinafine HCl 250mg tabletsLamisil® 250 mg Tablets
brief summary
The purpose of this study is to evaluate the relative bioavailability of the test formulation of terbinafine tablets with an already marketed reference formulation Lamisil® (Novartis Pharmaceuticals), under fasted conditions in healthy, non-tobacco using male and female adult subjects.
started
Jan 1, 2002
primary completion
Jan 1, 2002
completion
Jan 1, 2002
last updated
Aug 19, 2024
detailed description
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
official title
The Relative Bioavailability of Two Terbinafine HCl 250 mg Tablet Formulations Under Fasting Conditions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol